What’s Up with U.S. Merger Remedies? A Podcast Episode Featuring Jeny Maier
February 26, 2024, 3:14 PM
By: Axinn Insights
The US antitrust agencies’ approach to merger remedies has undergone a significant change under the Biden administration. Remedies are increasingly disfavored.
Axinn's Managing Partner Jeny Maier joins Dan Ducore, former Assistant Director of the Federal Trade Commission’s Bureau of Competition Compliance Division, and co-host Barry Nigro on Our Curious Amalgam to discuss the growing skepticism towards merger remedies by the US antitrust authorities.
Listen to this episode to learn more about whether merger remedies remain a viable option in the US and, if so, how parties should approach them given the government’s current hostility toward remedies.
To subscribe to our publications, click here.
Tags
News & Insights
News & Insights
IBA Annual Conference 2025
Speaking Engagement
Antitrust
Thomson Reuters 24th Annual Law Firm COO & CFO Forum
Speaking Engagement
LegalNEXT 2025
Speaking Engagement
Antitrust
Informa Antitrust Texas 2025
Speaking Engagement
Antitrust
ACI Forum on Pharma & Biotech Patent Litigation USA 2025
Speaking Engagement
Intellectual Property
MCCA Gala 2025
Sponsorship
Antitrust
Antitrust 101: Trial-Minded Antitrust Discovery
Webinar
Antitrust
ABA Antitrust Plaintiffs' Roundtable 2025
Speaking Engagement
Antitrust
Centerforce IP Strategy Summit: Palo Alto
Speaking Engagement
Intellectual Property
Corporate Counsel Women, Influence, & Power in Law Conference 2025
Speaking Engagement
Antitrust